Question 1

Can you mix peptides, and does mixing them work?

Accepted Answer

Combining peptides is not unusual in itself, and approved medicine does it routinely. A 2021 review of the GLP-1 class, the injections behind semaglutide and liraglutide, records that these agents can be combined with (basal) insulin in either free- or fixed-dose preparations. Research peptides sit somewhere else entirely. A 2026 primer for orthopaedic surgeons on the most popular injectable peptides concluded that information regarding the indications, dosing, frequency, and duration of treatment remains unknown. A second compound multiplies those unknowns rather than adding one. So the question of whether mixing peptides works has two different answers. For a handful of approved pairings, trials measured it in people. For most stacks sold under research names, the question has not been asked in people at all.

Question 2

What shouldn't you mix with peptides?

Accepted Answer

The list on record is short. An interaction only gets written down when someone looks for one, and that has mostly happened in the trials that lead to approval. Bremelanotide, the injection approved for low sex drive in women before menopause, was tested on 3500 subjects in 43 completed studies. Its safety review found that most drug-drug interactions were not clinically significant, except for interactions that lowered plasma concentrations of indomethacin and naltrexone. The first is a painkiller and the second is used for alcohol and opioid dependence. Another review of the same work found no clinically significant interactions with ethanol. Increlex, an approved IGF-1 medicine for a rare growth disorder in children, comes with a rule of a different kind. A Canadian payer said it should be paid for only if it is not prescribed in combination with recombinant growth hormone treatment. That is a reimbursement rule rather than a safety finding. Past these, no study among the research behind this page names a research peptide that must never meet another, and that is not the same as any pair being cleared.

Question 3

What not to mix with semaglutide and the other GLP-1 drugs?

Accepted Answer

For this class the interaction questions begin in the stomach. Every member slows the rate at which a meal leaves it, and a 2021 review lists deceleration of gastric emptying preventing large post-meal glycemic increments among the mechanisms that all GLP-1 receptor agonists share. Whether that slower stomach changes how a tablet taken alongside is absorbed is a fair question, and the reviews behind this page describe the slowing without measuring what it does to any other medicine. The same review notes that effects on gastric emptying decrease over time (tachyphylaxis). The second question is low blood sugar. In that review's words the class has no intrinsic risk of hypoglycemic episodes, while a 2022 review of diabetes therapy observes that insulins still induce hypoglycaemia and weight gain in many patients. So the risk sits in what semaglutide is combined with rather than in semaglutide alone, and insulin or another glucose-lowering medicine is where it concentrates. The semaglutide record on its own is taken apart on the Semaglutide safety page.

Question 4

Does tirzepatide or retatrutide interact with other medicines?

Accepted Answer

Tirzepatide has the better record of the two, and even that record is mostly about what it was added on top of. A 2022 meta-analysis pooled seven trials in 6609 adults with type 2 diabetes. It found that incidence of hypoglycaemia with tirzepatide was similar vs placebo and lower vs basal insulin. The authors are careful about how far that goes, and point to generalisation of findings mainly to individuals who are overweight or obese and already on metformin-based background therapy. So metformin is the partner with the most people behind it, and the supplements readers ask about do not show up in these trials at all. Retatrutide is one molecule acting on three hormone receptors at once, and a 2025 review says that a GLP-1/GIP/GCG triple agonist may offer superior weight loss efficacy over GLP-1 agonist alone. None of the sources for this page tests retatrutide beside another medicine, so that question goes to the Retatrutide safety page, and the tirzepatide trials are read in full on the Tirzepatide safety page.

Question 5

Which peptide combinations have been tested in people?

Accepted Answer

Nearly all of them pair an approved peptide medicine with another approved medicine, since that is the only place anyone funds a controlled trial of a pair. In the SCALE Insulin trial, adults with obesity and diabetes who already used insulin were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198) for 56 weeks. More hypoglycemic events were observed with placebo than liraglutide 3.0 mg. A 2025 trial added efruxifermin, a new liver medicine, in people already on a GLP-1 drug, giving efruxifermin 50 mg (n = 21) or placebo (n = 10) for 12 weeks. Its authors found that the tolerability profile of efruxifermin added to GLP-1RA appeared comparable to that of either drug alone. Cerebrolysin, a peptide mix made from pig brain, was tried with the dementia pill donepezil, and the trial showed beneficial effects on global measures and cognition for all three treatment groups compared with baseline. Read that carefully: patients in each arm got better against their own starting point, and that does not establish that the pair beat either medicine on its own.

Question 6

What happens when a peptide is paired with exercise or nutrients?

Accepted Answer

Some of the best-controlled combination data has nothing to do with a second injection. A Danish trial randomised 195 adults with obesity, after an 8-week low-calorie diet, to exercise, liraglutide, both, or placebo for a year. In the trial's bone analysis, liraglutide treatment alone reduced BMD at clinically relevant sites more than exercise alone despite similar weight loss. BMD is bone mineral density, a measure of how strong bone is. A second look at the same trial found that liraglutide alone did not improve physical fitness, while exercise did, with or without the medicine. Collagen peptides have been tested the same way. In a 12-week trial of older men with sarcopenia, which is muscle lost with age, the effect was significantly more pronounced in subjects receiving collagen peptides alongside weight training than in those given a dummy powder. A 2025 meta-analysis reported that when collagen was paired with the nutrients vitamin D and calcium, positive synergies were noticed. These are stacks of a different kind, where the partner is training or a vitamin. They show what a tested pairing looks like.

Question 7

Which combinations have only been tried in animals?

Accepted Answer

A longer list sits in rodents, and each one answers a narrow question set up for one experiment. In mice, according to a 2026 primer for surgeons, CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss. Tetanic tension is a measure of peak muscle force, and the same primer adds that these findings are limited to animal studies. In fat mice on a western diet, combining BAM15 with either semaglutide dose decreased body fat and liver triglycerides, which was not achieved by any monotherapy. BAM15 is a test compound that makes cells burn energy less efficiently. In male rats given the antidepressant paroxetine, humanin co-administration significantly reversed these adverse effects on sex drive, sperm and hormones. Each is a real result, but a mouse given two known compounds for a set number of weeks is not a person stacking vials for months.

Question 8

Does stacking two peptides add their effects together?

Accepted Answer

Sometimes, in the narrow sense the word synergy has in a lab. Growth-hormone secretagogues, the class that holds hexarelin and ipamorelin, were described in a 1999 study as molecules that even at low doses, truly synergize with GHRH, the body's own signal to release growth hormone. A review the same year called the combined administration of GHRH and GHRP-6 the most powerful GH releasing stimulus known in obesity. Both describe tests in which a single dose is given to provoke a growth-hormone peak, and a one-hour peak is not evidence about weeks of daily shots. In mice drinking alcohol, a low dose of melanotan-II produces a 7.6-fold increase in the effectiveness of naltrexone at cutting binge drinking. The amylin compound cagrilintide and semaglutide appear to have an additive effect on appetite reduction. Synergy is a measured property of one pair in one model, and it does not carry over to a different pair.

Question 9

What is the best stack, and which peptides should be stacked?

Accepted Answer

No ranking appears on this page, and the reason is structural rather than cautious. Ranking stacks would need each one tested as a stack, against the same endpoint, in comparable people, and among the research behind this page that has not happened for any combination of research peptides. What the field did instead is telling. Rather than stacking separate compounds, incretin research folded several actions into one molecule. A 2025 review describes the emergence of unimolecular polypharmacology, which utilizes single molecules to simultaneously target multiple receptors or pathways, and tirzepatide is the first approved result. Where two compounds stay separate, they are tested as a pair: cagrilintide is now being developed in combination with the GLP-1 agonist semaglutide, with its own trials. That is the difference between a combination and a stack. A combination earns a record of its own, while a stack borrows the records of its parts and assumes they add up. The evidence for each compound alone is set out on the researched-effects overview, compound by compound.

Question 10

What peptides should not be stacked together?

Accepted Answer

The clearest documented harm from a combination sits in a single person. A 2022 case report followed a 25-year-old man taking LGD-4033, a selective androgen receptor modulator, with MK-677, an oral growth-hormone secretagogue, daily for five weeks. Over that cycle his alanine aminotransferase, a liver enzyme, rose by 205.0%, his high-density lipoprotein cholesterol fell by 36.4%, and his total testosterone fell by 62.3%. The authors note that all variables returned to pre-cycle values post-cycle, apart from total fat mass, appendicular fat mass, bone area, total cholesterol and low-density lipoprotein-cholesterol. That is the problem with every stack in miniature. One man took two compounds, so the report cannot say which caused what, or whether either would have done it alone. A 2026 scoping review adds that MK-677 was associated with significant risks including congestive heart failure. Neither source supplies a list of forbidden pairs. What they show is that when a combination goes wrong, the record cannot say which part of it was responsible.

Question 11

What is known about stacking growth-hormone peptides and IGF-1 LR3?

Accepted Answer

This is the family most often stacked, and a 2026 review was written to help doctors make sense of it. It lists the agents seen in clinics, from CJC-1295 and ipamorelin to IGF-1 Long R3 (IGF-1 LR3). The side effects it records include prolactin and cortisol elevations, appetite changes, and dysglycaemia, which means blood sugar that will not stay steady. It also names the uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains as part of what a doctor is up against. The one IGF-1 pairing among these sources points the other way from a stack built for more effect. Mecasermin rinfabate joins IGF-1 to its own binding protein, and a 2006 review says it was developed to prolong the half-life and to counteract acute adverse events (particularly hypoglycaemia) associated with administration of IGF-I. The partner was there to make IGF-1 gentler, not stronger. What the growth-hormone peptides do one at a time is on the CJC-1295 comparison page and the Ipamorelin comparison page, and the IGF-1 record is on the IGF-1 safety page.

Question 12

What has thymosin alpha-1 been combined with?

Accepted Answer

Thymosin alpha-1, sold as thymalfasin, has more pairing data than any research peptide on this page, and almost all of it sets it beside an established antiviral or cancer medicine. In chronic hepatitis B, small pilot studies with interferon or a nucleoside analogue, a class of antiviral pill, reported a 70% complete sustained response rate. Early hepatitis C studies pointed the same way, but a large phase III trial in Europe, in people who had not responded to standard therapy, found that thymalfasin did not improve the rate of sustained virologic responses, though it cut relapse in those who finished. That is the usual order: a striking pilot, then a bigger trial with a smaller answer. In lung cancer, a review of the records of 120 patients given it beside immunotherapy, with or without chemotherapy, found that the incidence of AEs, including myelosuppression and gastrointestinal reactions, was comparable across groups. AEs are adverse events, and the patients were not randomised, so the groups may have differed from the start. The pairings, trial by trial, are set out at the Thymosin Alpha-1 comparison page.

Question 13

What to stack with MOTS-c, SS-31 or kisspeptin?

Accepted Answer

For these three, the combination evidence among the studies behind this page is close to empty. MOTS-c appears in a 2025 rat study of lung damage after heart surgery, where exogenous MOTS-c administration in rats attenuated lung injury by reducing oxidative damage, inflammation, and mortality. It was given alone, with no partner, so the result describes MOTS-c and not any stack that holds it. SS-31 does not turn up in a combination study anywhere among these sources. Kisspeptin turns up only in a hormone review, which says that progesterone acts via its receptors on the kisspeptin, neurokinin B, and dynorphin neurons in the hypothalamus. That is how the body works, not a test of two compounds given together. The compound pages hold the rest: The MOTS-c comparison page covers the pairings MOTS-c has met, the Kisspeptin comparison page does the same for kisspeptin, and the SS-31 overview sets out where that compound stands.

Question 14

What are the Wolverine, GLOW and KLOW blends, and has BPC-157 been stacked?

Accepted Answer

These are commercial names for fixed stacks. The Wolverine stack is BPC-157 (body protection compound 157) with TB-500, a synthetic fragment of thymosin beta-4; GLOW adds GHK-Cu (copper tripeptide-1) to those two, and KLOW adds the tripeptide KPV on top of that. The human record for any of them stops at a 2021 retrospective chart review of knee pain, in which four patients received BPC-157 together with thymosin beta-4. Of those patients, 75% improved and 25% had no relief of their knee pain, and the review itself states that the use of peptides BPC157 and thymosin-beta-4 (TB4) has not been studied in that setting. That is weaker than it looks: four people, with no control group, telephoned months later. On TB-500 separately, a 2026 primer found that TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking. Each blend has its own page reading the evidence component by component, at the Wolverine stack overview, the GLOW blend overview and the KLOW blend overview, with the BPC-157 comparisons on the BPC-157 comparison page.

Question 15

Can two peptides be mixed in the same vial or syringe?

Accepted Answer

That is a question about chemistry inside a container rather than about effects inside a body, and it has a page of its own at the handling and storage overview. The short version is that compatibility belongs to the exact mixture that was tested. A pharmacy selling a combined injection formulated it against data of its own, which two vials combined at home do not come with. How ingredients are joined can matter a great deal. In a 2026 artificial skin model, a bonded GHK delivery system delivered 9.72 ng/cm2 of GHK, more than five-fold higher than the physical mixture of spicules and free GHK. That was a laboratory skin model rather than a person, but it shows why a mixture cannot be assumed to behave like its ingredients.

Question 16

What is still unknown about combining peptides?

Accepted Answer

Most of it, and the gaps are named by the reviewers themselves rather than by us. A 2026 review of peptides in ageing says significant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy. A 2026 scoping review of six sports peptides found that significant heterogeneity existed in dosing and route of administration, so even single-compound studies are hard to line up. The study that would answer a stacking question gives one group each compound alone, one group both and one group neither, then measures the same outcome in all of them. Without the single-compound arms, a good result from a stack cannot be credited to the stack. Among the studies behind this page, that design appears for exercise with liraglutide and in a few animal experiments, and not for any combination of research peptides in people.

Peptide stacking: what is known about combinations